{"denoms":[{"counts":[{"groupId":"BG000","value":"113"},{"groupId":"BG001","value":"110"},{"groupId":"BG002","value":"223"}],"units":"Participants"}],"groups":[{"description":"Participants received platinum-containing anticancer treatment regimens (with or without pembrolizumab) at the study center as chosen by the treating investigator based on NSCLC histology. Participants with NSCLC of non-squamous histology received carboplatin + pemetrexed or cisplatin + pemetrexed or pembrolizumab + carboplatin + pemetrexed or pembrolizumab + cisplatin + pemetrexed. Participants with NSCLC of squamous histology received carboplatin or cisplatin + gemcitabine or carboplatin + paclitaxel/nab-paclitaxel + pembrolizumab until PD or for up to a maximum of 2 years.","id":"BG000","title":"Arm A: Treatment Period- SOC"},{"description":"Participants received pralsetinib, 400 mg, QD on Day 1 of each cycle until PD, PTAP, pralsetinib was no longer available, unacceptable toxicity, non-compliance, withdrawal of consent, closure of the study by the sponsor, or death, whichever occurred first (cycle length=21 days).","id":"BG001","title":"Arm B: Treatment Period- Pralsetinib"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"12.3","value":"62.3"},{"groupId":"BG001","spread":"11.1","value":"61.6"},{"groupId":"BG002","spread":"11.7","value":"61.9"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"64"},{"groupId":"BG001","value":"53"},{"groupId":"BG002","value":"117"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"49"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"106"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"37"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"77"},{"groupId":"BG001","value":"82"},{"groupId":"BG002","value":"159"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"27"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"16"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"43"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"4"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"65"},{"groupId":"BG001","value":"68"},{"groupId":"BG002","value":"133"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"4"}],"title":"Other"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"4"}],"title":"Unknown"},{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"19"}],"title":"Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}],"populationDescription":"Intent-to-Treat (ITT) population included all randomized participants whether or not the assigned study treatment is received."}